Evaluation of percutaneous cryoneurotomy compared with surgical open neurotomy for the management of post-stroke spastic equinovarus foot in France: protocol for a multicentre, randomised controlled, open-label, non-inferiority trial
Abstract
Abstract Introduction A primary complication following stroke is the impairment of the pyramidal tract and parapyramidal fibres, leading to upper motor neuron syndrome and subsequent spasticity. The most frequent lower limb manifestation is spastic equinovarus foot (SEF), a deformity involving abnormal plantar flexion, inversion and adduction. Current management most often begins with focal botulinum toxin injections. However, their efficacy is transient, necessitating repeated treatments. Alternatively, surgical neurotomy offers a more permanent solution but carries the risks associated with surgical invasiveness and potential complications. Percutaneous CryoNeurotomy (CN) has recently emerged as a minimally invasive alternative that may provide long-term relief. While preliminary case reports are promising, the comparative efficacy and safety of CN in SEF patients have yet to be established via a randomised controlled trial. Methods and analysis The CRYOSTROKE study is a multicentre, controlled and randomised open-label, non-inferiority trial with two parallel arms. A total of 114 patients with refractory post-stroke spastic equinovarus foot will be enrolled across several French centres over a 24-month period. To determine eligibility, a routine perineural motor nerve block will be performed by the treating physician to differentiate spasticity from muscle contracture, in accordance with the 2018 guidelines from the SFAR (French Society of Anaesthesia and Intensive Care) and SOFMER (French Society of Physical and Rehabilitation Medicine). Eligible patients will be randomised 1:1 and allocated to either Surgical Neurotomy (SN; control group) or CryoNeurotomy (CN; intervention group). Follow-up assessments will be conducted at 90-, 180-, and 365-day post-intervention. The primary endpoint is the mean absolute change in spasticity from baseline to Day 90, as measured by the Modified Ashworth Scale (MAS) (range: 0–4). The MAS will be assessed during passive ankle dorsiflexion with the knee fully extended (180°). At the 90-day mark, if the MAS score has decreased by one grade or less, a repeat perineural block will be performed to investigate potential treatment failure. For the CN group, if spasticity remains predominant (positive outcomes after perineural motor nerve block), a second cryoneurotomy procedure will be offered. If the anaesthetic block indicates predominant retraction, a complementary orthopaedic intervention (combined surgery) will be performed. For patients in the SN group, regardless of the block test results, subsequent management (eg, repeat SN, combined surgery or orthopaedic approach) will follow the standard of care at the respective centre. The secondary outcomes include mean absolute change in functional disability, passive ankle dorsal flexion movement spasticity, maximal ankle range of motion in slow and rapid movement, walking performance, physical activity intensity, pain intensity, interference and surface, quality of life, fatigue, goal attainment, patient satisfaction and rate of revisions from baseline and at 90, 180 and 365-day follow-up periods. Ethics and dissemination The study was approved by the French Agency for the Safety of Health Products (ANSM, Agence National de Sécurité du Médicament) as well as by the Ethics Committee (CPP Sud-Ouest et Outre-Mer III) N°ID-RCB : 2024-A02399-38. Recruitment began in July 2025 and ended on June 2027. As of 30 June 2026, 30 patients have been included in the study. The results will be published in peer-reviewed journals and disseminated to participants and community health institutions. Trial registration number NCT06726434.